Skip to content
LexBuild

Center for Scientific Review; Notice of Closed Meetings

---
identifier: "/us/fr/2022-04619"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Center for Scientific Review; Notice of Closed Meetings"
title_number: 0
title_name: "Federal Register"
section_number: "2022-04619"
section_name: "Center for Scientific Review; Notice of Closed Meetings"
positive_law: false
currency: "2022-03-04"
last_updated: "2022-03-04"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2022-04619"
document_type: "notice"
publication_date: "2022-03-04"
agencies:
  - "Health and Human Services Department"
  - "National Institutes of Health"
fr_citation: "87 FR 12466"
fr_volume: 87
---

#  Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Vascular Regulation and Diseases.

*Date:* March 29, 2022.

*Time:* 1:00 p.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Ai-Ping Zou, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118, MSC 7814, Bethesda, MD 20892, (301) 408-9497, *[email protected].*

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Neuroimaging, Neuropsychiatric Disorders, and Developmental Neurobiology.

*Date:* March 30, 2022.

*Time:* 9:00 a.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Health, 6701 Rockledge Dr., Bethesda, MD 20817 (Virtual Meeting).

*Contact Person:* Lai Yee Leung, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1011D, Bethesda, MD 20892, (301) 435-1042, *[email protected].*

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; RFA-OD19-029: The Intersection of Sex and Gender Influences on Health and Disease.

*Date:* March 30-31, 2022.

*Time:* 10:00 a.m. to 8:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Elaine Sierra-Rivera, Ph.D., Scientific Review Officer, EMNR IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6182, MSC 7892, Bethesda, MD 20892, (301) 435-2514, *[email protected].*

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Traumatic Brain Injury, Hemorrhage and Fluid Dynamics.

*Date:* March 30, 2022.

*Time:* 1:00 p.m. to 7:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Pat Manos, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5200, MSC 7846, Bethesda, MD 20892, (301) 408-9866, *[email protected].*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 1, 2022.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.